文献速递类风湿关节炎

类风湿关节炎不良健康结局预测模型的开发与外部验证:一项跨国真实世界队列分析

Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis.
PubMed 文献 · Semin Arthritis Rheum · 2022-06-15

本研究利用9个国家15个理赔与电子健康记录数据库,在21,547例起始一线甲氨蝶呤单药治疗的类风湿关节炎患者中开发并内部验证不良健康结局预测模型,并在131,928例患者中外部验证。严重感染、心肌梗死和卒中模型判别力良好且校准充分,其他结局模型内部判别力有限且未行外部验证。

要点

  • 严重感染模型AUC内部0.74、外部0.62至0.83,判别力良好且校准充分。
  • 心肌梗死模型AUC内部0.76、外部0.56至0.82,判别力良好且校准充分。
  • 卒中模型AUC内部0.77、外部0.63至0.95,判别力良好且校准充分。

核心结论

  • 研究开发并验证了起始一线甲氨蝶呤单药治疗的类风湿关节炎患者多种不良健康结局预测模型。
  • 严重感染、心肌梗死和卒中最终模型在多个数据库中表现良好,可研究用于临床。

研究设计与样本

  • 使用9个国家15个理赔与电子健康记录数据库的数据。
  • 在Optum®去标识化Clinformatics® Data Mart Database上使用L1正则化逻辑回归开发并内部验证模型,在其他所有数据库进行外部验证。
  • 候选预测因子包括人口学变量和既往病史。
  • 模型开发与内部验证纳入21,547例类风湿关节炎患者,外部验证纳入131,928例类风湿关节炎患者。
  • 预测结局包括治疗开始后3个月内(白细胞减少、全血细胞减少、感染)、2年内(心肌梗死和卒中)和5年内(癌症[结直肠癌、乳腺癌、子宫癌])。

主要发现

  • 严重感染模型AUC内部0.74、外部0.62至0.83,判别力良好且校准充分。
  • 心肌梗死模型AUC内部0.76、外部0.56至0.82,判别力良好且校准充分。
  • 卒中模型AUC内部0.77、外部0.63至0.95,判别力良好且校准充分。
  • 其他结局模型内部判别力有限(AUC<0.65),未进行外部验证。

关键数值与推荐

  • 严重感染模型AUC:内部0.74,外部0.62至0.83。
  • 心肌梗死模型AUC:内部0.76,外部0.56至0.82。
  • 卒中模型AUC:内部0.77,外部0.63至0.95。
  • 其他结局模型内部AUC<0.65,未外部验证。

临床怎么用

  • 严重感染、心肌梗死和卒中最终模型在多个数据库中表现良好,可研究用于临床。

局限性

  • 其他结局模型内部判别力有限(AUC<0.65),未进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of rheumatoid arthritis (RA) patients at high risk of adverse health outcomes remains a major challenge. We aimed to develop and validate prediction models for a variety of adverse health outcomes in RA patients initiating first-line methotrexate (MTX) monotherapy. METHODS: Data from 15 claims and electronic health record databases across 9 countries were used. Models were developed and internally validated on Optum® De-identified Clinformatics® Data Mart Database using L1-regularized logistic regression to estimate the risk of adverse health outcomes within 3 months (leukopenia, pancytopenia, infection), 2 years (myocardial infarction (MI) and stroke), and 5 years (cancers [colorectal, breast, uterine] after treatment initiation. Candidate predictors included demographic variables and past medical history. Models were externally validated on all other databases. Performance was assessed using the area under the receiver operator characteristic curve (AUC) and calibration plots. FINDINGS: Models were developed and internally validated on 21,547 RA patients and externally validated on 131,928 RA patients. Models for serious infection (AUC: internal 0.74, external ranging from 0.62 to 0.83), MI (AUC: internal 0.76, external ranging from 0.56 to 0.82), and stroke (AUC: internal 0.77, external ranging from 0.63 to 0.95), showed good discrimination and adequate calibration. Models for the other outcomes showed modest internal discrimination (AUC < 0.65) and were not externally validated. INTERPRETATION: We developed and validated prediction models for a variety of adverse health outcomes in RA patients initiating first-line MTX monotherapy. Final models for serious infection, MI, and stroke demonstrated good performance across multiple databases and can be studied for clinical use. FUNDING: This activity under the European Health Data & Evidence Network (EHDEN) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Yang C, Williams RD, Swerdel JN, et al. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis. Semin Arthritis Rheum. 2022. PMID: 35728447. doi:10.1016/j.semarthrit.2022.152050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。